Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 4/20 | 0.42 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.35 |
| ▸ | GCK | P35557 | 2/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5373073 | 0.84 | MEN1 (0.46) | GLO1MAOBMEN1KMT2A | |
| SCHEMBL15712213 | 0.78 | FGFR1 (0.50) | GLO1ENPP3ENPP1FGFR1FGFR4 | |
| SCHEMBL20873242 | 0.73 | GLO1 (0.49) | GLO1ENPP3ENPP1FGFR1FGFR4 | |
| SCHEMBL484088 | 0.73 | FGFR1 (0.39) | GLO1ENPP3ENPP1FGFR1FGFR4 | |
| SCHEMBL31126947 | 0.72 | FGFR1 (0.44) | GLO1ENPP3ENPP1FGFR1FGFR4 | |
| SCHEMBL16160086 | 0.72 | FGFR1 (0.40) | GLO1ENPP3ENPP1FGFR1FGFR4 | |
| SCHEMBL857211 | 0.69 | FGFR1 (0.43) | GLO1ENPP3ENPP1FGFR1FGFR4 | |
| SCHEMBL1417507 | 0.68 | DGAT1 (0.46) | GLO1ENPP3ENPP1FGFR1FGFR4 | |
| SCHEMBL7859822 | 0.67 | HTR7 (0.42) | ENPP3ENPP1FGFR1FGFR4 | |
| SCHEMBL15528344 | 0.67 | ALDH1A1 (0.41) | ENPP3ENPP1HDAC8MAOBGCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235550-B2 | Polycyclic azaindole compounds | LES LABORATOIRES SERVIER (FR) | 2007-06-26 | — | — | US | disclosed |
| US-6667304-B2 | Affinity for melatonin receptors; sleep disorders; N-(2-(2-methoxy-6H-pyrido(2',3':4,5)pyrrolo(2,1-a)isoindol-11 -yl)ethyl)acetamide; N-(2-(3-methoxy-6,7,8,9-tetrahydropyrido (3,2-b)indolizin-5-yl) ethyl)acetamide | LES LABORATOIRES SERVIER (FR) | 2003-12-23 | — | — | US | disclosed |
| US-20030134847-A1 | New polycyclic azaindole compounds | GUILLAUMET GERALD (FR) | 2003-07-17 | — | — | US | disclosed |
| US-20030105087-A1 | For therapy of melatoninergic disorders | GUILLAUMET GERALD (FR) | 2003-06-05 | — | — | US | disclosed |
| EP-1092717-B1 | Polycyclic azaindole derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-01-08 | — | — | EP | disclosed |
| US-6495543-B1 | TREATING OR PREVENTING MELATONINERGIC DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-12-17 | — | — | US | disclosed |
| EP-1092717-A2 | Polycyclic azaindole derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134847-A1 | New polycyclic azaindole compounds | AZI2, DRD3, CCNI | GLO1 3818/4885ENPP3 3264/4885ENPP1 2940/4885 |
| US-20030105087-A1 | For therapy of melatoninergic disorders | MTNR1A, MTNR1B, TPH1 | GLO1 879/4885ENPP3 4068/4885ENPP1 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.